Trial Profile
An Open-label Study to Assess the Potential for Pre-systemic Inhibition of Cytochrome P450 3A4 (CYP3A) by Idebenone in Healthy Male Subjects Using Midazolam as a Substrate
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Idebenone (Primary) ; Midazolam (Primary)
- Indications Duchenne muscular dystrophy; Leber's hereditary optic atrophy; Multiple sclerosis
- Focus Pharmacokinetics
- Sponsors Santhera Pharmaceuticals
- 23 Nov 2016 Status changed from not yet recruiting to completed.
- 22 Sep 2016 New trial record